

May 20, 2026

OrganTech Grants Domestic Manufacturing License for Hair Follicle Cell-Derived Components Including the “Third Cell Type”

OrganTech, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Yoshio Shimo; hereinafter “OrganTech”), a company engaged in the development of innovative medical technologies aimed at improving health and quality of life (QOL), hereby announces that it has granted Kojin Bio Co., Ltd. (Headquarters: Sakado, Saitama; President: Takato Nakamura; hereinafter “Kojin Bio”) a domestic manufacturing license for cell-derived components from hair follicle cells, including the “third cell type” (hair follicle regeneration-supporting cells) and dermal papilla cells.




Fig. 1. Hair follicle-derived cell populations involved in hair follicle regeneration




Fig. 2. Hair follicles regenerated in vitro using the third cell type

This licensing agreement marks the second business collaboration between OrganTech and Kojin Bio, following their collaboration on three-dimensional artificial skin technology. Hair follicle epithelial stem cells and dermal papilla cells play essential roles in the regeneration of the hair follicle organ responsible for hair production. In February 2026, OrganTech became the first in the world to identify “hair follicle regeneration-supporting cells,” a previously unknown “third cell type” capable of inducing hair follicle organ regeneration (*). Meanwhile, Kojin Bio has been developing and marketing proprietary optimized culture media capable of supporting the cultivation of dermal papilla cells and hair follicle regeneration-supporting cells.

Through this agreement, OrganTech has granted Kojin Bio the domestic manufacturing rights for these cell-derived components in Japan. By combining Kojin Bio's proprietary cell culture media and cell processing technologies with OrganTech's regenerative technologies, the two companies aim to expand business development in the hair and skin fields.

OrganTech positions this licensing agreement as one of its key initiatives involving hair follicle-related cells. Going forward, the company plans to accelerate research and development of hair regenerative medicine technologies — including cell-based therapies, hair follicle germ transplantation, and regenerated hair follicle transplantation — as well as a wide range of products utilizing cell-derived components. These activities will be pursued in collaboration with medical institutions and corporate partners. Companies interested in joint development are encouraged to contact us via the information below.

In the fields of hair and skin healthcare, OrganTech remains committed to solving various healthcare challenges, including alopecia, skin disorders, and aging, through the accumulation of scientific evidence and continued technological innovation. The company aims to contribute to a society where people can enjoy improved health, well-being, and quality of life.

***Publication Information**

- **Title:** Fully Functional Hair Follicle Organ Regeneration Using Organ-Inductive Potential Stem Cells with an Accessory Mesenchymal Cell Population in an In Vitro Culture System
- **Authors:** Koh-ei Toyoshima, Ayako Tsuchiya, Miho Ogawa, Miki Takase, Tarou Irié, Masayuki Yanagisawa, Richard H. Kaszynski, Hiroshi Fujimaki, Kyoko Baba, Takayuki Sugimoto, Akira Takeda, Akio Sato, and Takashi Tsuji
- **Journal:** Biochemical and Biophysical Research Communications
- **Volume:** 810
- **Year:** 2026
- **Article Number:** 153459
- **DOI:** <https://doi.org/10.1016/j.bbrc.2026.153459>

Contact Information

OrganTech Inc.

Tel: +81-3-5859-5761

Email: info [at] organ-tech.jp

Please replace “[at]” with “@” when sending emails.